DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Mellitus, Type 2

Intervention: Metformin, 500 mg extended release tablet (Drug); Metformin, 1000 mg extended release tablet (Drug); Glimepiride, 1 mg immediate release tablet (Drug); Glimepiride, 2 mg immediate release tablet (Drug); Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers (Drug); Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers (Drug); Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers (Drug); Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers (Drug)

Phase: Phase 1

Status: Terminated

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline


This is a an open-label, randomized, single dose, four-way crossover, multi-stage study enrolling 20 healthy adult male and female subjects per part. This study consists of two separate parts (Part A and B) with each part comprising four treatment periods. Each subject will participate in all four treatment periods per part; Subjects may not enrol in both Parts A and B. This study is being conducted to compare the pharmacokinetics (PK) of two extended release fixed dose combinations (FDC) oral formulations of metformin and glimepiride at two doses, 500mg/1mg and 1000mg/2mg, with each FDC formulation to be administered orally as a single dose and compared with the commercially available formulations of metformin extended release (XR) (GLUCOPHAGE ™ Sustained Release [SR]) and glimepiride immediate release (IR) (AMARYL ™). Part A of study will evaluate the bioavailability of a formulation comprising a film coated tablet containing release controlling polymers; and Part B will evaluate the bioavailability of a formulation comprising a tablet coated with release controlling polymers. In each part there will be 4 treatment periods. During each period, subjects will be randomized sequentially to receive a single dose of a reference treatment of 500 mg metformin XR / 1 mg glimepiride IR; and a reference treatment of 1000 mg metformin XR / 2 mg glimepiride IR; and an FDC tablet containing 500 mg metformin XR and 1 mg glimepiride XR; and an FDC tablet containing 1000 mg metformin XR and 2 mg glimepiride XR. Serial PK sampling for up to 36 hours and safety assessments will be performed. Each period will be separated by a washout period of at least 5 days and a follow-up visit will occur 14 days after the last dose of study drug.

Clinical Details

Official title: An Open-Label, Randomized, Single Dose, Four-way Crossover, Multi-stage Study to Determine the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations, 500 mg or 1000 mg Extended Release Metformin and 1 mg or 2 mg Extended Release Glimepiride, in Healthy Adult Male and Female Subjects in the Fed State

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Cmax of metformin

AUC(0-t) and AUC(0-inf) for metformin and glimepiride

Secondary outcome:

Tmax and t1/2 of of metformin and glimepiride

Percentage AUCex for metformin and glimepiride; and AUC(0-∞), AUC (0-t) for metformin and glimepiride in relevant treatments

Number of subjects with adverse events (AE)s


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Healthy male or female subjects between 18 and 65 years of age inclusive with body

weight >= 50 kg and body mass index (BMI) within the range 19 to 32 kilogram/meter squared

- Alanine aminotransferase (ALT) alkaline phosphatase and bilirubin limit of normal (ULN).

- Normal ECG measurements. Average QT duration corrected for heart rate by Fridericia's

formula (QTcF) <450 millisecond or QTcF <480 msec in subjects with Bundle Branch Block based on an average from three electrocardiograms (ECGs) obtained over a brief recording period.

- Female subjects of non-child bearing potential. Females of child bearing potential

are eligible to enter if they are not pregnant and willing to use protocol-specified methods of contraception to prevent pregnancy until 14 days post-last dose of metformin/glimepiride.

- Capable of giving written informed consent

Exclusion Criteria:

- The subject has a positive: drug/alcohol screen, Hepatitis, HIV screen

- Abuse of alcohol

- Current or chronic history of liver disease, or known hepatic or biliary


- Exposure to more than four new investigational chemical entities within 12 months

prior to the first dosing day

- Participated in a clinical trial and has received an investigational product within

the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)

- Sensitivity to any of the study medications, or components thereof or a history of

drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation

- Donation of more than 500 mL blood within a 56 day period

- Pregnant or lactating females

- Unwillingness or inability to follow the procedures outlined in the protocol

- Subject is mentally or legally incapacitated

- Subject having positive urinary cotinine levels indicative of use of tobacco or

nicotine-containing products within 6 months prior to screening.

- Unable to refrain from consumption of red wine, Seville oranges, grapefruit or

grapefruit juice from 7 days prior to the first dose

- Subjects having asthma or are positive carbon monoxide (CO) on admission to the Unit

- Unable to refrain from the use of prescription or non-prescription drugs within 7

days prior to first dose of study medication, unless approved by the Investigator and GSK Medical Monitor.

Locations and Contacts

GSK Investigational Site, Randwick, New South Wales 2031, Australia
Additional Information

Starting date: September 2012
Last updated: November 27, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017